Maxim downgraded NeuroSense (NRSN) to Hold from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRSN:
- NeuroSense Receives FDA Approval for Phase 3 Study of ALS Treatment
- NeuroSense concludes Type C meeting with FDA for PrimeC treatment
- NeuroSense files to sell 6.6M ordinary shares for holders
- NeuroSense’s PrimeC Shows Promise in ALS Treatment
- NeuroSense announces ‘positive’ results from the PARADIGM study